Hill 43 InvestorsObserver puts shares of Lyell Immunopharma Inc (LYEL) near the middle of the biotechnology industry. In addition to scoring more than 39% of biotech industry stocks, LYEL’s overall rating of 43 means the stock scores better than 43% of all stocks.
What do these notes mean?
Finding the best stocks to invest in can be difficult. There are thousands of options and it can be confusing to know what really constitutes great value. InvestorsObserver lets you choose from eight unique metrics to display the top industries and top performing stocks within that industry. A score of 43 would be higher than 43% of all actions. These rankings allow you to easily compare stocks and see what the strengths and weaknesses of a given company are. This allows you to find the stocks with the best short-term and long-term growth prospects in seconds. The combined score incorporates technical and fundamental analysis to provide a comprehensive view of a stock’s performance. Investors who then want to focus on analyst rankings or valuations can see separate scores for each section.
What’s going on with Lyell Immunopharma Inc stock today?
Lyell Immunopharma Inc (LYEL) stock is up 4.61% while the S&P 500 is down -0.08% at 3:24 p.m. Wednesday, January 25. LYEL is $0.14 higher than the previous closing price of $3.04 on volume of 431,391 shares. . Over the past year, the S&P 500 is -7.87% lower while LYEL is -41.65% lower. LYEL has lost -$1.04 per share over the past 12 months. Click here for the full Lyell Immunopharma Inc. stock report.
Stay in the know
Subscribe to our daily morning update newsletter and never miss market news, moves and more.